Latest Breaking News On - Responsive auto regulatory element - Page 1 : vimarsana.com

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesHayleigh collinsSeanp nolanHead of corporate communicationsEuropean commissionTaysha gene therapies incCompany contactExchange commissionDrug administrationDevelopment expensesData monitoring committeeRegulatory agencyRegenerative medicine advanced therapyGene therapiesChief executive officerUnited states food

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Initiation of REVEAL pediatric trial in the U.S.broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Ret.

United kingdomUnited statesUniversity medical centerElizabeth berry kravisSukumar nagendranCarolyn hawleyHayleigh collinsCompany contactExchange commissionTaysha gene therapies incHead of corporate communicationsCanale communicationsEuropean commissionRegulatory agencyUt southwestern gene therapy programUnited statesbroadens

StockWatch: Seven Analysts Cut Price Target for Taysha on FDA Advice, Job Cuts

StockWatch: Seven Analysts Cut Price Target for Taysha on FDA Advice, Job Cuts
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United statesSukumar suku nagendranSilvan tuerkcanEun yangSeanp nolanGil blumJoon leeCanaccord genuityJackk allenWhitney ijemEuropean commission orphan drugTaysha gene therapiesChair seanMotor function measureAstellas gene therapyClinical trial application

Taysha Gene Therapies: TSHA-102 s Potential Is A Buy (NASDAQ:TSHA)

Taysha Gene Therapies: TSHA-102 s Potential Is A Buy (NASDAQ:TSHA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesEuropean unionTaysha gene therapies incEuropean society of gene cell therapyRegenerative medicineGene therapiesCentral nervous systemTrack designationEuropean societyCell therapyResponsive auto regulatory elementRett syndromeClinical trial applicationFast track designation

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly e.

United kingdomUnited statesCarolyn hawleyElsa rossignolHayleigh collinsSukumar nagendranTaysha gene therapies incRegulatory agencyDrug administrationCompany contactHead of corporate communicationsCanale communicationsEuropean commissionUt southwestern gene therapy programData monitoring committeeExchange commission